ArticleChemical communications (Cambridge, England)2014
Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells.
Article in Chemical communications (Cambridge, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Aptamer-Based Targeting of Cancer: A Powerful Tool for Diagnostic and Therapeutic Aims.Biosensors · 2024Review
- Structure and dynamics of an archetypal DNA nanoarchitecture revealed via cryo-EM and molecular dynamics simulations.Nature communications · 2023Article
- Metal Cluster Triggered-Assembling Heterogeneous Au-Ag Nanoclusters with Highly Loading Performance and Biocompatible Capability.International journal of molecular sciences · 2022Article
- Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers.Frontiers in cell and developmental biology · 2022Review
- Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques.International journal of nanomedicine · 2022Review
- Recent advances in surface modification of micro- and nano-scale biomaterials with biological membranes and biomolecules.Frontiers in bioengineering and biotechnology · 2022Review
- Design and clinical developments of aptamer-drug conjugates for targeted cancer therapy.Biomaterials research · 2021Review
- Functional DNA-Polymer Conjugates.Chemical reviews · 2021Review
- Review
- Importance of Nano Medicine and New Drug Therapies for Cancer.Advanced pharmaceutical bulletin · 2021Review
- Lipid-oligonucleotide conjugates for bioapplications.National science review · 2020Article
- Multifunctional Albumin-Stabilized Gold Nanoclusters for the Reduction of Cancer Stem Cells.Cancers · 2019Article
- Nanoparticle Activation Methods in Cancer Treatment.Biomolecules · 2019Review
- Recent Advances in Degradable Hybrids of Biomolecules and NGs for Targeted Delivery.Molecules (Basel, Switzerland) · 2019Review
- Dual-mode imaging and therapeutic effects of drug-loaded phase-transition nanoparticles combined with near-infrared laser and low-intensity ultrasound on ovarian cancer.Drug delivery · 2018Article
- Cross-Linked Aptamer-Lipid Micelles for Excellent Stability and Specificity in Target-Cell Recognition.Angewandte Chemie (International ed. in English) · 2018Article
- Aptamer-based targeted therapy.Advanced drug delivery reviews · 2018Review
- Fluorinated DNA Micelles: Synthesis and Properties.Analytical chemistry · 2018Article
- Self-Assembled Aptamer-Nanomedicine for Targeted Chemotherapy and Gene Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2018Article
- Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects without Adverse Effects on Hepatic Lipid Metabolism in LdlrAdvanced healthcare materials · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A therapeutic aptamer-lipid-poly(lactide-co-glycolic acid) hybrid nanoparticle-based drug delivery system was prepared and characterized. This system can co-deliver two different drugs with distinct solubility and different anticancer mechanisms to target cancer cells with high specificity and efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.